A population-based cohort of adults with asthma: mortality and participation in a long-term follow-up

Helena Backman, Linnea Hedman, Caroline Stridsman, Sven-Arne Jansson, Anne Lindberg, Bo Lundbäck and Eva Rönmark

Background and objective: Asthma is a major public health concern. The aim of this study was to characterize a large population-based cohort of adults with asthma, and to study factors associated with all-cause mortality and non-participation in a long-term follow-up.

Design: Random and stratified samples from five population-based cohorts were clinically examined during 1986–2001, and all subjects with asthma were included in the study (n = 2055, age 19–72 years, 55% women). Independent associations between different risk factors and (i) mortality and (ii) non-participation in a clinical follow-up in 2012–2014 were estimated.

Results: In 1986–2001, 95% reported any wheeze and/or attacks of shortness of breath in the past 12 months, and/or asthma medication use. Over the up to 28 years of follow-up time, the cumulative mortality was 22.7%. Male gender, current smoking, and lower forced expiratory volume in 1 sec of predicted (FEV1% of predicted) were independent risk factors for mortality, while obesity was associated with non-participation in the follow-up. Older ages, ischemic heart disease, and low socioeconomic status were associated with both mortality and non-participation.

Conclusions: The risk factors associated with mortality in this adult population-based asthma cohort were similar to those commonly identified in general population samples, i.e. male gender, current smoking, and lower FEV1% of predicted, while obesity was associated with non-participation in a long-term follow-up. Ischemic heart disease, low socioeconomic status, and older ages were associated with both mortality and non-participation.

Introduction

Asthma is a major public health concern which places a considerable burden on society in terms of morbidity, mortality, and costs [1]. It is a common disease of differing severity presenting with several phenotypes [2]. Non-allergic childhood asthma often remits, while the majority of allergic childhood asthma persists into adulthood [3–6]. In contrast to childhood asthma, adult-onset asthma is often more persistent and non-atopic [7–9]. Despite a large number of studies on asthma, our ability to predict persistence, remission, or mortality is limited [10].

Subjects with asthma have long been reported to have excess all-cause mortality compared to subjects without asthma [11–13], although the excess mortality among subjects with asthma seems to be declining, according to recent studies [14–17]. This excess mortality risk is related to lower pre-bronchodilator forced expiratory volume in 1 sec (FEV1) [12,18–21] and large FEV1 bronchodilation response [22], but studies presenting factors associated with mortality among subjects with asthma are scarce.

Both the diagnosis and therapeutic management of asthma have changed during the past few decades, and asthma is more frequently diagnosed today than during the 1980s and 1990s [23,24]. Furthermore, general knowledge about asthma has increased in the community. Thus, there are likely to be differences over time in what a self-reported physician diagnosis in epidemiological studies represents. Therefore, not only diagnosis but also other factors such as respiratory symptoms, lung function, bronchial hyperreactivity, and medication use should be taken into account [24]. The participation rates in epidemiological studies
have declined over time [25,26], but whether and how this affects the results remains to be determined.

Long-term follow-ups of asthma cohorts enable studies on factors related to persistence, remission, relapse, and progression of the disease. As we still do not know how to prevent asthma, increased knowledge on factors related to disease progression can contribute significantly to improved public health. This knowledge is especially limited concerning adults. While patient-based asthma cohorts are more likely to include subjects with moderate and severe disease, population-based asthma cohorts represent the entire asthma population in a society. However, few well-characterized population-based asthma cohorts have been studied over the long term, although such studies are warranted [8].

The aim of this study was to characterize a large cohort of adults with asthma identified by clinical examinations of population-based samples in northern Sweden during 1986–2001. A further aim was to study factors associated with all-cause mortality and non-participation in a long-term follow-up of this population-based asthma cohort.

**Material and methods**

**Study area**

The study was performed in Norrbotten, the northernmost county of Sweden, with a population of about 250,000 inhabitants. The climate is subarctic, with long winters and short but warm summers. The study was performed as a part of the epidemiological research program the Obstructive Lung Disease in Northern Sweden (OLIN) studies and was approved by the Regional Ethical Review Board at Umeå University.

**Study sample**

The study sample consists of a large cohort of adults with asthma (n = 2055) (Figure 1) which was identified in clinical examinations of five previously described population-based cohorts within the OLIN studies. Informed consent was obtained from all individual participants included in the study. Initially, cohort 1 was an age-stratified total population sample recruited in 1985 (n = 5697; 86% of invited; 35–36, 50–51, 65–66 years) [27] from eight municipalities in the county of Norrbotten, and cohort 2 an age-stratified total population sample recruited in 1992 (n = 7735; 85% of invited; 20–21, 35–36, 50–51, 65–66 years) in the same municipalities. Cohorts 3 and 4 were random population samples from the entire county recruited in 1992 (cohort 3: n = 4851; 85% of invited; 20–69 years) [28] and 1996 (cohort 4: n = 7420; 85% of invited; 20–74 years) [29], while cohort 5 was a sample of subjects with an adult onset of asthma recruited in 1995–1999 (n = 309; 19–60 years) [5]. The first four cohorts were cross-sectional studies with the primary aim of studying prevalence and prevalence change. Random or stratified samples from these four cohorts were clinically examined during the years following recruitment, and all subjects who fulfilled the preset criteria for asthma in these clinical examinations were

**Figure 1.** Summary of the entire cohorts from where the asthma cohort was derived. The asthmatics were identified in clinical examinations of random and stratified samples of the cohorts.
Inclusion criteria at study entry in 1986–2001

The preset asthma criteria for inclusion in the asthma cohort depended on what types of clinical examinations the subjects underwent. In cohort 1, an evaluation by a physician at the time of examinations (year 1986) identified 398 subjects as having asthma or highly suspected asthma. In cohort 5, all 309 subjects had fulfilled the strict criteria for having an adult onset of asthma during the year preceding the examination [5]. Regarding cohorts 1–4, four preset inclusion criteria (A–D), based on data from structured interviews and clinical examinations including spirometry and tests of bronchial hyperreactivity for subsamples, are presented as follows:

(A) report of physician-diagnosed asthma or ever having had asthma
(B) wheeze with breathlessness without having a cold in the past 12 months (asthmatic wheeze) in combination with at least one of: (1) attacks of shortness of breath (SOB) or wheeze in the past 12 months caused by at least three different triggering factors, or (2) asthma medication use in the past 12 months; (C) attacks of SOB or any wheeze in the past 12 months in combination with positive methacholine challenge.

Clinical examinations at study entry in 1986–2001

The clinical examinations at study entry in 1986–2001 included detailed structured interviews about respiratory symptoms and diseases, associated risk factors, and comorbid conditions, and measurements of height, weight, and dynamic spirometry (Mijnhardt Vicatess 5 dry volume spirometer) using internally and externally validated local reference values [31]. Tests of reversibility and bronchial hyperresponsiveness, and skin-prick tests were performed in subsamples.

Clinical examinations at follow-up in 2012–2014

All subjects in the asthma cohort who were alive and still living in the county of Norrbotten (as recorded in the National Population Registry) were invited to a clinical follow-up in 2012–2014. Those who did not attend the follow-up examination despite several invitations were defined as non-participants. The examination included a detailed structured interview about respiratory symptoms and diseases, associated risk factors and comorbid conditions, occupation and educational level, measurements of height and weight, pre- and post-bronchodilator spirometry (Jaeger Masterscope pneumotach spirometer), skin-prick testing with 10 common airborne

| Table 1. Number of subjects fulfilling the different asthma inclusion criteria in the five population-based cohorts. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Cohort 1  (n = 544) | Cohort 2  (n = 858) | Cohort 3  (n = 164) | Cohort 4  (n = 180) | Cohort 5  (n = 309) | Total  (n = 2055) |
| Met any of the preset A, B, C, or D asthma criteria: | 146 | 858 | 164 | 180 | 0 | 1348 |
| Of which met criterion: | | | | | | |
| A | 71 | 539 | 79 | 99 | 0 | 398 |
| B | 85 | 647 | 113 | 113 | 0 | 395 |
| C | 12 | 34 | 12 | 7 | 0 | 23 |
| D | 0 | 0 | 44 | 65 | 0 | 109 |
| Physician diagnosis at examination of cohort 1: | 398 | 0 | 0 | 0 | 0 | 398 |
| Adult incident asthma in cohort 5: | 0 | 0 | 0 | 309 | 309 |

Each subject could fulfill one or several of the preset A, B, C, or D asthma criteria: (A) report of physician-diagnosed asthma or ever having had asthma; (B) wheeze with breathlessness without having a cold in the past 12 months (asthmatic wheeze) in combination with at least one of: (1) attacks of shortness of breath (SOB) or wheeze in the past 12 months caused by at least three different triggering factors, or (2) asthma medication use in the past 12 months; (C) attacks of SOB or any wheeze in the past 12 months in combination with FEV1 reversibility of both ≥ 12% and ≥ 200 ml; and (D) attacks of SOB or any wheeze in the past 12 months in combination with positive methacholine challenge.

Development of the asthma cohort

Included in the asthma cohort. Cohort 5 was a case–control study including subjects fulfilling the criteria for adult-onset asthma [5]. In general, the participation rates in these cohorts were high, with no or only limited bias due to non-participation [26].

PC20 ≤ 8 mg/ml according to a rapid method developed within the OLIN studies [5].
allergens in those aged ≤ 60 years, and blood sampling. Data from the asthma control test (ACT), Global Initiative for Asthma (GINA) classification, health-related quality of life measured by the eight-item Short-Form Health Survey (SF-8) questionnaire, and data regarding occupational exposures were also collected. Reasons for non-participation were recorded. Mortality dates were collected from the National Population Registry up until the date of invitation to the clinical examinations.

The follow-up time in years was defined as the time between study entry and death among deceased subjects, between study entry and invitation among those who had moved from the county or did not participate (non-participants), and between study entry and date of examination among participants in the clinical follow-up.

Statistical analyses

In bivariate analyses, the chi-squared test was used to test for differences in proportions and the Student’s t test for differences in means. Tests for differences in means across more than two groups were performed by analysis of variance (ANOVA). A p value < 0.05 was considered statistically significant.

Poisson regressions (with robust errors) were performed to identify factors associated with (i) mortality and (ii) non-participation in the clinical follow-up in 2012–2014. Age (numeric), gender (women as reference), body mass index (BMI) categories (normal weight as reference), smoking habits (never-smoking as reference), and socioeconomic groups based on occupation (manual workers in service as reference) were considered as potential risk factors and included in the models. The follow-up time was included as an offset variable in the models. Furthermore, as a proxy for the time of study entry, i.e. the start of the follow-up period, all models were also adjusted for initial cohort (cohort 1–5 described earlier). The results are presented as relative risks (RRs) with 95% Wald confidence intervals (CIs) and p values. Pre-bronchodilator FEV₁% of predicted was included in secondary versions of the models, and so were asthma medication use, ischemic heart disease, and FEV₁/forced vital capacity (FVC) < lower limit of normal (LLN) [31], respectively. Overall, there were very few internal missing data on specific questions and measures. Subjects with missing data were included in the multivariate analyses with the missing data labeled ‘missing’, and the results of this variable are not presented.

Sensitivity analyses

The main Poisson regression analyses of mortality were performed in several subgroups and these results are presented in Supplementary Table 1. The subgroups are based on cohort, year of birth, gender, follow-up time, age at asthma onset, smoking habits, and BMI. Also, the main Poisson regression analyses of non-participation were performed including subjects who declined to participate (n = 276) as non-participants only, compared to participants (n = 1006). Owing to signs of over-dispersion in some models, negative binomial regression with the dispersion parameter included in the models was used as an alternative regression approach. Also, the Poisson regression models were performed without including the follow-up time as an offset variable.

Results

Sample characteristics and participation in the follow-up

Figure 1 describes the identification of the asthma cohort in the clinical examinations of samples from the five cohorts during the study entry years 1986–2001. In total, 2055 subjects fulfilled the preset asthma criteria and were included in the asthma cohort. The numbers (n) of subjects from each cohort who fulfilled the different preset asthma criteria are presented in Table 1.

During the follow-up time, the cumulative mortality was 22.7% (n = 466) (Figure 2). At the time of invitation to the clinical follow-up, 1425 subjects were still alive and living in the county of Norrbotten. These were subsequently invited to the follow-up, in which 71% (n = 1006) participated while 29% (n = 419) did not (Figure 2). The mean (min–max) follow-up time was 18.7 (10–28) years among both participants and non-participants in the follow-up, which was similar to 18.5 (10–26) years among those who had moved from the county. The mean time (min–max) between study entry and death among the deceased was 14.2 (0.5–28) years.

The sample characteristics at study entry are presented in Table 2 (separate results for women and men are presented in Supplementary Table 2). The mean age among the 2055 subjects was 45.4 years and did not differ between men and women. About one-third of the asthma cohort (30.3%) was current smokers and 16.0% were obese at study entry. The participants (n = 1006) were younger than non-participants (n = 419) at study entry (40.5 vs 45.6 years; p < 0.001), and less predominantly female (55.4% vs
63.0%; \( p < 0.001 \). The mean age among male participants and non-participants was 40.6 and 42.9 years (\( p = 0.051 \)), compared to 40.4 and 47.2 years (\( p < 0.001 \)) among female participants and non-participants, respectively. Subjects who were alive but had moved from the county at the time of invitation to the follow-up (\( n = 164 \)) had the lowest mean age (33.0 years) and were least often obese (11.6%). In contrast,
the 466 deceased subjects were oldest at study entry (mean age 60.1 years) and also tended to be most frequently obese (18.7%). Also, the distribution of socioeconomic status differed between the subgroups (Table 2).

The prevalence of respiratory symptoms differed between subgroups, and was largest among those deceased by the time of follow-up (Table 3, with separate results for women and men presented in Supplementary Table 3). Among all 2055 subjects, 77.1% either had attacks of SOB or used asthma medicines, and 95.3% had any wheeze or attacks of SOB or used asthma medicines at study entry. When comparing participants with non-participants in the follow-up, 94.2% and 95.2% (p = 0.453), respectively, had any wheeze or attacks of SOB or used asthma medicines at study entry. The prevalence of allergic comorbid conditions was lowest while the prevalence of ischemic heart disease and FEV₁/FVC < LLN was highest among those deceased by the time of follow-up, and these subjects also had the lowest mean values of both FEV₁ and FVC at study entry (Table 3).

**Factors independently associated with mortality**

Male gender, current smoking, and older age were significantly and independently associated with mortality (Table 4). The significance for ex-smoking was lost when FEV₁% of predicted was included in the model, and decreased FEV₁ was significantly associated with mortality. Neither any asthma medication use nor FEV₁/FVC < LLN was a significant risk factor or changed any of the estimates for the other factors when included in the models, but ischemic heart disease was significantly associated with mortality. With manual workers in service as reference, self-employed non-professionals had a lower mortality risk.

### Table 3. Prevalence (%) of asthma-related characteristics, respiratory symptoms, comorbidities and lung function at study entry in 1986–2001 among all subjects and within different subgroups based on participation in the clinical follow-up in 2012–2014.

| Asthma-related characteristic | Subgroup in clinical follow-up in 2012–2014 | All subjects in the asthma cohort |
|------------------------------|---------------------------------------------|----------------------------------|
|                              | Participants n = 1006 | Invited non-participants n = 419 | Had moved from county at time of invitation n = 164 | Deceased at time of invitation n = 466 | p | n = 2055 |
| Family history of asthma (%)| 41.2 | 42.0 | 41.5 | 33.5 | 0.023 | 39.6 |
| Any asthma medication in past 12 months (%)| 36.6 | 37.9 | 36.0 | 48.9 | <0.001 | 39.6 |
| Age (years) at asthma onset (%)| | | | | | |
| Pre-school age | 15.1 | 13.4 | 19.7 | 10.5 | 0.070 | 14.2 |
| School age up to 15 years | 13.7 | 12.3 | 15.6 | 6.2 | 0.004 | 12.0 |
| 16–30 years | 25.0 | 26.4 | 32.8 | 10.2 | <0.001 | 22.8 |
| > 30 years | 46.2 | 47.8 | 32.0 | 73.1 | <0.001 | 51.1 |
| Respiratory symptoms (%)| | | | | | |
| Attacks of SOB | 72.2 | 69.0 | 72.6 | 62.2 | 0.001 | 69.3 |
| Any wheeze in past 12 months | 88.9 | 89.3 | 87.2 | 79.1 | <0.001 | 90.0 |
| Recurrent wheeze | 78.0 | 78.3 | 74.4 | 77.9 | 0.755 | 77.8 |
| Asthmatic wheeze | 76.3 | 74.5 | 76.8 | 81.3 | 0.082 | 77.1 |
| Persistent wheeze | 23.9 | 25.1 | 25.0 | 44.2 | <0.001 | 28.8 |
| Night-time sleep disturbance due to breathlessness or wheeze in past 12 months | 40.2 | 43.7 | 40.2 | 60.7 | <0.001 | 45.5 |
| Comorbid conditions (%)| | | | | | |
| Rhinitis | 53.5 | 50.8 | 56.7 | 45.9 | 0.026 | 51.5 |
| Ever hayfever | 43.3 | 38.7 | 53.0 | 25.3 | <0.001 | 39.1 |
| Ever eczema | 35.5 | 33.7 | 42.7 | 22.7 | <0.001 | 32.8 |
| Ischemic heart disease | 3.6 | 10.3 | 0.6 | 29.4 | <0.001 | 10.6 |
| FEV₁/FVC < LLN | 8.3 | 10.1 | 7.5 | 25.1 | <0.001 | 12.4 |
| Lung function (mean values) | | | | | | |
| FEV₁% of predicted | 88.4 | 85.7 | 90.3 | 68.7 | <0.001 | 83.6 |
| FVC% of predicted | 87.0 | 84.8 | 88.1 | 70.8 | <0.001 | 83.0 |
| FEV₁/FVC | 0.81 | 0.79 | 0.82 | 0.73 | <0.001 | 0.79 |
| Z score FEV₁ | −1.05 | −1.25 | −0.90 | −2.56 | <0.001 | −1.42 |
| Z score FVC | −1.12 | −1.25 | −1.07 | −2.28 | <0.001 | −1.40 |
| Z score FEV₁/FVC | 0.21 | 0.13 | 0.40 | −0.60 | <0.001 | 0.03 |
| FEV₁ reversibility (%) | | | | | | |
| < 12% | 86.0 | 81.4 | 92.5 | 66.3 | <0.001 | 78.7 |
| 12–20% | 10.0 | 11.4 | 5.7 | 18.7 | 0.007 | 13.0 |
| 20% | 4.1 | 7.1 | 1.9 | 15.0 | <0.001 | 8.3 |

*p* = Chi-square test for difference between subgroups.

**n** = 790 women and 374 men lacked information on age at asthma onset (information on asthma onset was not included in the interview for cohort 1, and lacking for a few subjects in the other cohorts), **n** = 27 lacked adequate spirometry data.

*Reversibility testing results are only available from a subgroup of 710 subjects from cohorts 1 and 2: in cohort 1, subjects with forced expiratory volume in 1 sec (FEV₁) < 85% were invited for reversibility testing (n = 273 participated); in cohort 2, subjects with FEV₁ < 90% or FEV₁/FVC < 0.7 were invited for reversibility testing (n = 437 participated).

SOB, shortness of breath; LLN, lower limit of normal.
Table 4. Risk factor analysis for mortality by Poisson regression, with results presented as risk ratio (RR) with 95% confidence interval (CI).

| Covariate                              | Unadjusted | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|----------------------------------------|------------|---------|---------|---------|---------|---------|
|                                        | RR (95% CI)| RR (95% CI)| RR (95% CI)| RR (95% CI)| RR (95% CI)| RR (95% CI)|
| Male gender                            | 1.37 (1.16–1.60) | 1.40 (1.15–1.71) | 1.40 (1.15–1.71) | 1.40 (1.15–1.71) | 1.38 (1.13–1.69) | 1.40 (1.15–1.71) |
| Smoking                                |            |         |         |         |         |         |
| Current smoker                         | 1.64 (1.33–2.02) | 1.84 (1.49–2.27) | 1.57 (1.27–1.93) | 1.57 (1.27–1.93) | 1.56 (1.27–1.93) | 1.57 (1.27–1.94) |
| Ex-smoker                              | 1.84 (1.51–2.26) | 1.34 (1.10–1.63) | 1.15 (0.94–1.40) | 1.15 (0.94–1.40) | 1.13 (0.92–1.37) | 1.15 (0.94–1.40) |
| BMI<sup>a</sup>                         |            |         |         |         |         |         |
| Underweight                            | 0.64 (0.37–1.11) | 0.86 (0.48–1.56) | 0.77 (0.43–1.38) | 0.77 (0.42–1.39) | 0.78 (0.44–1.39) | 0.77 (0.43–1.38) |
| Overweight                             | 1.38 (1.14–1.67) | 0.95 (0.80–1.13) | 0.98 (0.82–1.18) | 0.98 (0.82–1.18) | 0.96 (0.80–1.16) | 0.98 (0.82–1.18) |
| Obese                                  | 1.44 (1.14–1.80) | 1.03 (0.82–1.30) | 1.10 (0.87–1.38) | 1.10 (0.87–1.38) | 1.07 (0.85–1.36) | 1.09 (0.86–1.38) |
| Socioeconomic group<sup>b</sup>        |            |         |         |         |         |         |
| Manual workers in industry             | 1.36 (1.10–1.67) | 1.02 (0.79–1.32) | 1.02 (0.80–1.32) | 1.02 (0.80–1.32) | 0.99 (0.77–1.28) | 1.02 (0.80–1.32) |
| Assistant non-manual employees         | 0.83 (0.63–1.09) | 0.79 (0.59–1.04) | 0.83 (0.63–1.09) | 0.83 (0.63–1.09) | 0.80 (0.61–1.07) | 0.83 (0.63–1.10) |
| Intermediate non-manual employees      | 0.51 (0.36–0.72) | 0.71 (0.50–1.01) | 0.74 (0.52–1.05) | 0.74 (0.52–1.05) | 0.73 (0.52–1.04) | 0.74 (0.52–1.05) |
| Professionals and executives           | 0.91 (0.57–1.46) | 0.89 (0.55–1.45) | 0.79 (0.49–1.27) | 0.79 (0.49–1.27) | 0.78 (0.48–1.27) | 0.79 (0.49–1.27) |
| Self-employed non-professionals        | 1.11 (0.75–1.65) | 0.61 (0.39–0.95) | 0.60 (0.38–0.93) | 0.60 (0.38–0.93) | 0.58 (0.37–0.91) | 0.60 (0.38–0.93) |
| Students and homemakers                | 0.59 (0.37–0.92) | 1.35 (0.90–2.04) | 1.43 (0.94–2.18) | 1.43 (0.94–2.19) | 1.38 (0.92–2.08) | 1.43 (0.93–2.18) |
| Others<sup>c</sup>                     | 2.18 (1.74–2.73) | 1.09 (0.84–1.41) | 1.02 (0.79–1.31) | 1.02 (0.79–1.31) | 1.00 (0.77–1.29) | 1.02 (0.79–1.32) |
| Age                                    | 1.09 (1.08–1.10) | 1.10 (1.09–1.11) | 1.09 (1.08–1.10) | 1.09 (1.08–1.10) | 1.08 (1.07–1.09) | 1.09 (1.08–1.10) |
| FEV₁, % of predicted                   | 0.97 (0.96–0.97) | 0.98 (0.98–0.99) | 0.98 (0.98–0.99) | 0.98 (0.98–0.99) | 0.98 (0.98–0.99) | 0.98 (0.98–0.99) |
| Any asthma medication                  | 1.46 (1.25–1.71) | 1.01 (0.86–1.19) | 1.01 (0.86–1.19) | 1.01 (0.86–1.19) | 1.01 (0.86–1.19) | 1.01 (0.86–1.19) |
| Ischemic heart disease                 | 3.53 (3.06–4.06) | 2.37 (2.01–2.80) | 2.37 (2.01–2.80) | 2.37 (2.01–2.80) | 2.37 (2.01–2.80) | 2.37 (2.01–2.80) |
| FEV₁/FVC < LLN                         | 0.98 (0.79–1.22) | 0.98 (0.79–1.22) | 0.98 (0.79–1.22) | 0.98 (0.79–1.22) | 0.98 (0.79–1.22) | 0.98 (0.79–1.22) |

All covariates/factors were measured at study entry. All models were also adjusted for original cohort at study entry and with follow-up time included as an offset variable.

Model 1 includes 2019 subjects (21.3% mortality) with complete data, while models 2–5 include 1999 subjects (21.3% mortality) with complete data.

<sup>a</sup>Underweight = body mass index (BMI) < 20; normal weight = 20 ≤ BMI < 25 (reference category); overweight = 25 ≤ BMI < 30; obese = BMI ≥ 30 kg/m².

<sup>b</sup>Manual workers in service (n = 638) is the reference category for socioeconomic group.

<sup>c</sup>Data missing, unable to classify, or unemployed without report on previous occupation.

Bold figures indicate statistical significance (p < 0.05).

FEV₁, forced expiratory volume in 1 sec; FVC, forced vital capacity; LLN, lower limit of normal.
Factors independently associated with non-participation

Older age and a history of ischemic heart disease at study entry were significantly and independently associated with non-participation in the 2012–2014 follow-up (Table 5). Neither gender, nor FEV₁% of predicted, nor any asthma medication use was a significant risk factor or changed any of the estimates for the other factors when included in the models. Obesity was only borderline significant in adjusted analyses except for when FEV₁/FVC < LLN was included in the model, and then obesity reached significance. With manual workers in service as reference, non-manual employees were participants to a larger extent.

Sensitivity analyses

The sensitivity analyses in different subgroups are presented in Supplementary Table 1 and confirmed the main results of significant risk factors for mortality.

The main results for both mortality and non-participation were also similar in the negative binomial regressions with the dispersion parameter included in the models, and in the Poisson regressions performed without including the follow-up time as an offset variable.

Discussion

This study provides a detailed characterization of a cohort identified in clinical examinations of population-based samples during 1986–2001. At the time-point of the examinations, 95% of the subjects experienced respiratory symptoms common in asthma and/or used asthma medicines. The main findings were that male gender, current smoking, older age, lower FEV₁% of predicted, and ischemic heart disease at study entry were independent risk factors for mortality among adult subjects with asthma followed over 10–28 years. Furthermore, in this long-term follow-up, older ages, obesity, and ischemic heart disease were independently associated with non-participation. Lower socioeconomic status was associated with both mortality and non-participation in our study. These results provide an excellent platform on which to base further studies on persistence, remission, disease severity, and progress, including health-related quality of life and asthma control, and related factors. Longitudinal studies of adult asthma cohorts are warranted [8] and our study adds important knowledge to this field.

Within the European Community Respiratory Health Survey (ECRHS), both population-based samples and samples including subjects with asthma only have been studied longitudinally [32–35]. Among adults with asthma defined as a positive answer to either ‘Do you have or have you ever had asthma?’ or ‘Have you ever had asthma diagnosed by a doctor?’ aged 20–44 years at baseline in the RHINE study [32], the Nordic part of the ECRHS, 60% were females and 53% had allergic rhinitis, 63% had wheezing in the past 12 months, and 78% had any asthma symptom in the past 12 months at baseline. In our study, 95% had any wheeze or attacks of SOB or used asthma medicines, which implies more specific asthma criteria. Our current population-based asthma cohort was clinically examined at both study entry and follow-up, and can thus provide valuable results on asthma remission in future studies.

Several studies have compared all-cause [36–39] or cause-specific [36,38] mortality among subjects with and without asthma in population-based studies. These studies indicate that subjects with asthma have an increased risk of all-cause mortality which is related to the baseline FEV₁ level [12,36,38,39], although the increased risk seems to be on the decrease [14,15,17]. However, independent risk factors for mortality among subjects with asthma are seldom presented in population-based studies or for well-characterized population-based asthma cohorts. In our study, we found that subjects with asthma had the same risk factors for mortality as most general population samples, such as male gender, older age, low FEV₁, and smoking. One Danish study performed during 1974–1990, based on clinical examinations of patients with known or suspected asthma identified by general practitioners, indicated that baseline FEV₁% of predicted, FEV₁ reversibility, and smoking were independent risk factors for asthma-specific mortality among patients with asthma, both allergic and non-allergic [22]. In our study, lower socioeconomic status was also associated with mortality, a result in line with others [40]. Disease severity assessed by symptom burden and detailed data on asthma medicine use, as well as asthma control, may also be of importance for the risk of death from asthma, but more detailed analyses of our data set is required. However, in our study, low FEV₁ was an independent factor related to mortality. As FEV₁ may be a marker of disease severity we can speculate that having severe asthma is related to increased risk of mortality.

The participation rates in epidemiological studies have been declining over time, and more rapidly during the past few decades. Attempts to study
Table 5. Risk factor analysis for non-participation (invited but did not participate) in the 2012–2014 follow-up by Poisson regression, with results presented as risk ratio (RR) with 95% confidence interval (CI).

| Covariate          | Unadjusted | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|--------------------|------------|---------|---------|---------|---------|---------|
|                    | RR (95% CI)| RR (95% CI)| RR (95% CI)| RR (95% CI)| RR (95% CI)| RR (95% CI)|
| Male gender        | 0.87 (0.67–0.94) | 0.87 (0.71–1.06) | 0.88 (0.72–1.07) | 0.87 (0.72–1.07) | 0.87 (0.71–1.06) | 0.87 (0.71–1.06) |
| Smoking            |            |         |         |         |         |         |
| Current smoker     | 1.18 (0.99–1.42) | 1.14 (0.95–1.37) | 1.13 (0.94–1.35) | 1.06 (0.72–1.56) | 1.07 (0.73–1.57) | 1.12 (0.93–1.34) |
| Ex-smoker          | 0.93 (0.76–1.15) | 0.85 (0.69–1.04) | 0.84 (0.68–1.03) | 0.94 (0.78–1.14) | 0.95 (0.78–1.15) | 0.84 (0.68–1.03) |
| BMI                |            |         |         |         |         |         |
| Underweight        | 1.05 (0.72–1.54) | 1.07 (0.73–1.58) | 1.06 (0.72–1.56) | 1.06 (0.72–1.56) | 1.07 (0.73–1.57) | 1.06 (0.72–1.56) |
| Overweight         | 1.02 (0.84–1.23) | 0.94 (0.77–1.14) | 0.94 (0.78–1.14) | 0.94 (0.78–1.14) | 0.95 (0.78–1.15) | 0.94 (0.78–1.14) |
| Obese              | 1.38 (1.12–1.71) | 1.23 (0.99–1.52) | 1.23 (1.00–1.53) | 1.23 (1.00–1.53) | 1.22 (0.99–1.51) | 1.24 (1.01–1.54) |
| Socioeconomic group|            |         |         |         |         |         |
| Manual workers in industry | 0.80 (0.64–1.01) | 0.92 (0.70–1.20) | 0.90 (0.69–1.18) | 0.90 (0.69–1.18) | 0.90 (0.69–1.18) | 0.90 (0.69–1.18) |
| Assistant non-manual employees | 0.77 (0.60–0.99) | 0.78 (0.61–0.99) | 0.76 (0.59–0.98) | 0.76 (0.60–0.98) | 0.76 (0.59–0.97) | 0.76 (0.59–0.97) |
| Intermediate non-manual employees | 0.60 (0.46–0.79) | 0.65 (0.49–0.85) | 0.63 (0.48–0.83) | 0.63 (0.48–0.83) | 0.63 (0.48–0.83) | 0.63 (0.48–0.83) |
| Professionals and executives | 0.51 (0.28–0.93) | 0.57 (0.30–1.05) | 0.58 (0.31–1.07) | 0.58 (0.31–1.07) | 0.59 (0.32–1.09) | 0.57 (0.31–1.06) |
| Self-employed non-professionals | 0.96 (0.66–1.39) | 0.92 (0.65–1.31) | 0.92 (0.65–1.30) | 0.92 (0.65–1.30) | 0.91 (0.64–1.28) | 0.91 (0.65–1.30) |
| Students and homemakers | 0.82 (0.58–1.15) | 1.00 (0.71–1.42) | 1.00 (0.71–1.42) | 1.00 (0.70–1.41) | 1.00 (0.70–1.41) | 1.00 (0.71–1.41) |
| Other$^c$          | 0.94 (0.64–1.37) | 0.96 (0.65–1.42) | 0.94 (0.64–1.39) | 0.94 (0.64–1.39) | 0.94 (0.64–1.39) | 0.94 (0.64–1.39) |
| Age                | 1.02 (1.01–1.03) | 1.02 (1.01–1.03) | 1.02 (1.01–1.03) | 1.02 (1.01–1.03) | 1.02 (1.01–1.03) | 1.02 (1.01–1.03) |
| FEV$_1$% of predicted | 0.99 (0.99–1.00) | 1.00 (0.99–1.00) | 1.00 (0.99–1.00) | 1.00 (0.99–1.00) | 1.00 (0.99–1.00) | 1.00 (0.99–1.00) |
| Any asthma medication | 1.04 (0.88–1.23) | 1.04 (0.88–1.23) | 1.04 (0.88–1.23) | 1.04 (0.88–1.23) | 1.04 (0.88–1.23) | 1.04 (0.88–1.23) |
| Ischemic heart disease | 1.95 (1.56–2.43) | 1.32 (1.03–1.69) | 1.32 (1.03–1.69) | 1.32 (1.03–1.69) | 1.32 (1.03–1.69) | 1.32 (1.03–1.69) |
| Other$^c$          | 1.16 (0.89–1.51) | 1.16 (0.89–1.51) | 1.16 (0.89–1.51) | 1.16 (0.89–1.51) | 1.16 (0.89–1.51) | 1.16 (0.89–1.51) |

All covariates/factors were measured at study entry. All models are also adjusted for original cohort at study entry and with follow-up time included as an offset variable. Model 1 includes 1425 subjects (29.4% non-participants) with complete data, while models 2–5 include 1415 subjects (29.4% non-participants) with complete data.

$^a$Underweight = body mass index (BMI) < 20; normal weight = 20 ≤ BMI < 25 (reference category); overweight = 25 ≤ BMI < 30; obese = BMI ≥ 30 kg/m$^2$.

$^b$Manual workers in service (n = 451) is the reference category for socioeconomic group.

$^c$Data missing, unable to classify, or unemployed without report on previous occupation.

Bold figures indicate statistical significance ($p < 0.05$).

FEV$_1$, forced expiratory volume in 1 sec; FVC, forced vital capacity; LLN, lower limit of normal.
whether and how the decreasing participation rates affect the results have been made in studies on respiratory epidemiology [25,26,41–45], and the results all seem to indicate that non-participants typically are male, smokers, and younger subjects [26,44,45]. It can be reasonably assumed that prevalence estimates may be more affected by increasing non-participation than associations between a risk factor and an outcome [25,26]. Studies on non-participation in long-term follow-ups of population-based asthma cohorts are rare, and our study indicates that non-participants are typically female, although non-significantly in adjusted analyses, and older, which contrasts with the results based on general population samples [26,44,45]. This could probably be due to the facts that subjects with asthma may develop a more severe disease and more comorbid conditions with increasing age [2,46], that women may be more affected by their disease or have a more persistent disease with poorer prognosis [7,10], and/or that the proposed obese female late-onset asthma phenotype is severe and more progressive [7,46,47], making these subjects less prone or able to participate. The association with low socioeconomic status is also of interest, and prior studies of general population samples have shown similar results and that full-time work is associated with non-participation [44].

There are some weaknesses with our study that should be mentioned. For one, tests of reversibility and bronchial hyperreactivity were not available for all subjects. The inclusion criteria permit that subjects who have intermittent remission or who have grown out of their asthma are included in the asthma cohort. However, 95% of the subjects reported respiratory symptoms common in asthma and/or asthma medication use at study entry, which suggests that only a few with remission of asthma were included in this adult asthma cohort. Also, factors measured at study entry such as asthma medication use may not be accurate predictors over a 10–28 year follow-up period owing to changes in, for example, available treatments and treatment guidelines and practices. The strength of our study is the large and well-characterized population-based asthma cohort followed for a long time. Spirometry was performed according to guidelines and was only lacking for 27 out of the 2055 included subjects, the methods included well-validated questionnaires, and the examinations and interviews were performed by well-trained staff. The participation rates were high, both in the clinical examinations in which the asthma cohort was identified and in the follow-up. Furthermore, Sweden has a complete population registry with reliable information on the date of mortality.

In conclusion, in this population-based adult asthma cohort the vast majority experienced respiratory symptoms common in asthma and/or used asthma medications at study entry. The risk factors associated with mortality were similar to those commonly identified in general population samples. Obesity, ischemic heart disease, low socioeconomic status, and older ages were associated with non-participation in the long-term follow-up. The detailed characterization of the cohort provides an excellent platform on which to base future studies on persistence, remission, disease severity, and related factors.

Acknowledgements

The research staff within the OLIN-studies is acknowledged for excellent data collection throughout the years. Financial support was received mainly from the Swedish Heart & Lung Foundation, the Swedish Research Council, ALF – a regional agreement between Umeå University and Norrbotten County Council, Norrbotten County Council, the Swedish Asthma-Allergy Foundation, and Visare Norr. None of the funding sources had involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Author contributions

All authors have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, and (3) final approval of the submitted manuscript.

Disclosure statement

The authors have the following conflicts of interests to declare: Dr. Backman reports personal fees from Boehringer Ingelheim outside the submitted work; Dr. Hedman, Dr. Stridsman, and Dr. Jansson have nothing to disclose; Dr. Lindberg reports personal fees from AstraZeneca, personal fees from Novartis, personal fees from ActiveCare, and personal fees from Boehringer-Ingelheim outside the submitted work; Dr. Lundbäck reports grants from AstraZeneca, grants from GSK, personal fees from GSK, personal fees from Novartis, and personal fees from Novartis outside the submitted work; Dr. Rönmark reports unconditional grants from the Swedish Heart & Lung Foundation, the Swedish Research Council, ALF – a regional agreement between Umeå University and Norrbotten County Council, Norrbotten County Council,
the Swedish Asthma-Allergy Foundation, and Visare Norr during the conduct of the study.

**Funding**

This work was supported by the Swedish Heart & Lung Foundation, Swedish Research Council, Umeå University, Norrbotten County Council, Norrbotten County Council, Swedish Asthma-Allergy Foundation, and Visare Norr.

**Geolocation information**

The study area was the county of Norrbotten, Sweden.

**ORCID**

Caroline Stridsman  [http://orcid.org/0000-0001-6622-3838](http://orcid.org/0000-0001-6622-3838)

**References**

1. Jansson SA, Rönmark E, Forsberg B, et al. The economic consequences of asthma among adults in Sweden. Respir Med. 2007 Nov;101(11):2263–2270.
2. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012 May 4;18(5):716–725.
3. Rönmark E, Jonsson E, Lundbäck B. Remission of asthma in the middle aged and elderly: report from the obstructive lung disease in Northern Sweden study. Thorax. 1999 Jul;54(7):611–613.
4. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003 Oct 9;349(15):1414–1422.
5. Rönmark E, Andersson C, Nyström L, et al. Obesity increases the risk of incident asthma among adults. Eur Respir J. 2005 Feb;25(2):282–288.
6. Andersson M, Hedman L, Bjerg A, et al. Remission and persistence of asthma followed from 7 to 19 years of age. Pediatrics. 2013 Aug;132(2):e435–e442.
7. De Marco R, Locatelli F, Cerveri I, et al. Incidence and remission of asthma: a retrospective study on the natural history of asthma in Italy. J Allergy Clin Immunol. 2002 Aug;110(2):228–235.
8. de Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really different?. Eur Respir Rev. 2013 Mar;1;22(127):44–52.
9. Rönmark E, Lindberg A, Watson L, et al. Outcome and severity of adult onset asthma—report from the obstructive lung disease in northern Sweden studies (OLIN). Respir Med. 2007 Nov;101(11):2370–2377.
10. Sears MR Predicting asthma outcomes. J Allergy Clin Immunol. 2015 Oct;136(4):829–836. quiz 837.
11. Huovinen E, Kaprio J, Vesterinen E, et al. Mortality of adults with asthma: a prospective cohort study. Thorax. 1997 Jan;52(1):49–54.
12. Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. Copd. 2011 Dec;8(6):400–407.
13. Putcha N, Hansel NN. All-cause mortality in asthma. The importance of age, comorbidity, and socioeconomic status. Ann Am Thorac Soc. 2014 Oct;11(8):1252–1253.
14. Tual S, Godard P, Piau JP, et al. Asthma-related mortality in France, 1980–2005: decline since the last decade. Allergy. 2008 May;63(5):621–623.
15. Fuhrman C, Jouglé E, Uhry Z, et al. Deaths with asthma in France, 2000–2005: a multiple-cause analysis. J Asthma. 2009 May;46(4):402–406.
16. Finkelstein MM, Chapman KR, McIvor RA, et al. Mortality among subjects with chronic obstructive pulmonary disease or asthma at two respiratory disease clinics in Ontario. Can Respir J. 2011 Nov-Dec;18(6):327–332.
17. To T, Simatovic J, Zhu J, et al. Asthma deaths in a large provincial health system. A 10-year population-based study. Ann Am Thorac Soc. 2014 Oct;11(8):1210–1217.
18. Lange P, Ulrik CS, Vestbo J. Mortality in adults with self-reported asthma. Copenhagen City heart study group. Lancet. 1996 May 11;347(9011):1285–1289.
19. Ali Z, Dirks CG, Ulrik CS. Long-term mortality among adults with asthma: a 25-year follow-up of 1,075 outpatients with asthma. Chest. 2013 Jun;143(6):1649–1655.
20. Becker EC, Wolke G, Heinrich J. Bronchial responsiveness, spirometry and mortality in a cohort of adults. J Asthma. 2013 May;50(4):427–432.
21. Huang S, Vasquez MM, Halonen M, et al. Asthma, airflow limitation and mortality risk in the general population. Eur Respir J. 2015 Feb;45(2):338–346.
22. Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest. 1995 Jul;108(1):10–15.
23. Sears MR. Trends in the prevalence of asthma. Chest. 2014 Feb;145(2):219–225.
24. Lundbäck B, Backman H, Lötvall J, et al. Is asthma prevalence still increasing?. Expert Rev Respir Med. 2015;26:1–13.
25. de Marco R, Verlato G, Zanolin E, et al. Nonresponse bias in EC respiratory health survey in Italy. Eur Respir J. 1994 Dec;7(12):2139–2145.
26. Rönmark E, Lundqvist A, Lundbäck B, et al. Nonresponders to a postal questionnaire on respiratory symptoms and diseases. Eur J Epidemiol. 1999 Mar;15(3):293–299.
27. Lundbäck B, Nyström L, Rosenhall L, et al. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. Eur Respir J. 1991 Mar;4(3):257–266.
28. Larsson LG, Lindberg A, Franklin KA, et al. Symptoms related to obstructive sleep apnoea are common in subjects with asthma, chronic bronchitis and rhinitis in a general population. Respir Med. 2001 May;95(5):423–429.
29. Backman H, Hedman L, Jansson SA, et al. Prevalence trends in respiratory symptoms and asthma in relation to smoking - two cross-sectional studies ten years apart among adults in northern Sweden. World Allergy Organ J. 2014 Jan 2;7(1):1-4551-7-1.

30. Malmberg P, Larsson K, Thunberg S. Increased lung deposition and biological effect of methacholine by use of a drying device for bronchial provocation tests. Eur Respir J. 1991 Jul;4(7):890–898.

31. Backman H, Lindberg A, Oden A, et al. Reference values for spirometry - report from the obstructive lung disease in Northern Sweden studies. Eur Clin Respir J. 2015 Jul 20;2:26375. eCollection 2015. DOI: 10.3402/ecrj.v2.26375.

32. Holm M, Omenaas E, Gislason T, et al. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007 Jul;30(1):62–65.

33. Chinn S, Jarvis D, Burney P. European community respiratory health survey. Relation of bronchial responsiveness to body mass index in the ECRHS. European community respiratory health survey. Thorax. 2002 Dec;57(12):1028–1033.

34. Cerveri I, Cazzoletti L, Corsico AG, et al. The impact of cigarette smoking on asthma: a population-based international cohort study. Int Arch Allergy Immunol. 2012;158(2):175–183.

35. Pesce G, Locatelli F, Cerveri I, et al. Seventy years of asthma in Italy: age, period and cohort effects on incidence and remission of self-reported asthma from 1940 to 2010. Plos One. 2015 Oct 6;10(10):e0138570.

36. Lange P, Ulrik CS, Vestbo J. Mortality in adults with self-reported asthma. Copenhagen city heart study group. Lancet. 1996 May 11;347(9011):1285–1289.

37. Huovinen E, Kaprio J, Vesterinen E, et al. Mortality of adults with asthma: a prospective cohort study. Thorax. 1997 Jan;52(1):49–54.

38. Savage JH, Matsui EC, McCormack M, et al. The association between asthma and allergic disease and mortality: a 30-year follow-up study. J Allergy Clin Immunol. 2014 May;133(5):1484-7, 1487.e1-5.

39. Huang S, Vasquez MM, Halonen M, et al. Asthma, airflow limitation and mortality risk in the general population. Eur Respir J. 2015 Feb;45(2):338–346.

40. Bos V, Kunst AE, Keij-Deerenberg IM, et al. Ethnic inequalities in age- and cause-specific mortality in The Netherlands. Int J Epidemiol. 2004 Oct;33(5):1112–1119.

41. Kotaniemi JT, Hassi J, Kataja M, et al. Does non-responder bias have a significant effect on the results in a postal questionnaire study?. Eur J Epidemiol. 2001;17(9):809–817.

42. Eagan TM, Eide GE, Gulsvik A, et al. Nonresponse in a community cohort study: predictors and consequences for exposure-disease associations. J Clin Epidemiol. 2002 Aug;55(8):775–781.

43. Brøgger J, Bakke P, Eide GE, et al. Contribution of follow-up of nonresponders to prevalence and risk estimates: a Norwegian respiratory health survey. Am J Epidemiol. 2003 Mar 15;157(6):558–566.

44. Rönmark EP, Ekerljung L, Lötvall J, et al. Large scale questionnaire survey on respiratory health in Sweden: effects of late- and non-response. Respir Med. 2009 Dec;103(12):1807–1815.

45. Johannessen A, Verlato G, Benediktsdottir B, et al. Longterm follow-up in European respiratory health studies - patterns and implications. BMC Pulm Med. 2014 Apr 16;14:63-2466-14-63.

46. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012 May;42(5):650–658.

47. Amelink M, de Nijs SB, de Groot JC, et al. Three phenotypes of adult-onset asthma. Allergy. 2013;68(5):674–680.